BioSpace News Archive

After showing some unfavorable results for its data, AC Immune on Monday announced it will be getting back its Alzheimer’s disease candidates from Roche’s Genentech.

This week, Lori, Greg and Tyler discuss the first ⁠surge of IPO activity⁠ this year plus gene therapy pricing,

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc.

HippoFi’s biotechnology business PUR Biologics, proudly announces Scott Bauccio as its new Head of Sales.

Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and The Michael J. Fox Foundation for Parkinson’s Research, a non-profit organization dedicated to finding a cure for Parkinson’s disease, announced a research project to accelerate research on genetic risk factors associated with PD, specifically targeting the role of variants in the GBA gene.

Caris Life Sciences® announced that the company and collaborators within the Caris Precision Oncology Alliance™ will collectively present eight studies across four tumor types at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium, January 25-27, 2024 in San Francisco.

BD announced a collaboration agreement with Hamilton, a leading global manufacturer of laboratory automation technology, to develop automated applications together with robotics-compatible reagent kits to enable greater standardization and reduced human error when conducting large-scale single-cell multiomics experiments.

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg.

Axsome Therapeutics, Inc. today announced it will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets.